Navigation Links
Cardiome to Present at Bear Stearns Conference
Date:9/6/2007

ptember 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expresse
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , ... July 29, 2015 , ... ... Susan Bentley as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation's leading networking organization exclusively for professional women, boasting more ...
(Date:7/28/2015)... ... , ... Every July, since 2007, about 25 pediatric pulmonary hypertension (PH) patients ... television. They go to summer camp. , PH is incurable and life threatening, as ... pushes hard to get blood through arteries in the lungs narrowed by the disease. ...
(Date:7/28/2015)... ... July 28, 2015 , ... Jordan Valley Medical ... With The Guidelines®-Stroke Gold Plus Award for implementing specific quality improvement measures outline ... , The Get With The Guidelines-Stroke program recognizes hospitals that demonstrate at least ...
(Date:7/28/2015)... Hollywood, Fl (PRWEB) , ... July 28, 2015 ... ... opened its new Total Heart Center at Memorial Regional Hospital, providing expert, streamlined ... 19,000-square-foot center will be suited to provide extensive heart services under one roof, ...
(Date:7/28/2015)... Rosa, California (PRWEB) , ... July 28, 2015 , ... Santa Rosa’s The Press Democrat ... year in a row, Dr. Francisco Canales and Dr. Heather Furnas took the top spot ... the community, Dr. Furnas and Dr. Canales are proud to be bestowed such a prestigious ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Susan Bentley, Owner of Women's Wellness Options, Into its VIP Woman of the Year Circle 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 3Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3Health News:Memorial Cardiac And Vascular Institute Centralizes Cardiac Care Through It's New "Total Heart Center" At Memorial Regional Hospital 2Health News:Dr. Canales and Dr. Furnas Honored as Sonoma County’s Best Cosmetic Surgeons 2
... For the sixth year in a row, HireRight, ... screening solutions, has been named to Deloitte’s prestigious ... ranking of the 50 fastest growing technology, media, ... by Deloitte LLP, one of the nation’s leading ...
... SAN FRANCISCO, Oct. 27 Amgen (Nasdaq: AMGN ... WYE ), today announced,that ENBREL is the first biologic ... multiple measures of efficacy in moderate to,severe rheumatoid arthritis ... this analysis, the safety profile remained consistent with,continuous ENBREL ...
... Outlook, Low Stress & No Smoking Contribute to Healthy ... people who have a,positive outlook, lower stress levels, moderate ... no chronic health,conditions are more likely to thrive in ... issue of the Journals of Gerontology, Medical Sciences., ...
... -. Adaptis, a leading business process,outsourcing (BPO) ... Paul Bessembinders has joined the sales team ... efforts in the Western territory.,Bessembinders will report ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ), "Paul ...
... MONTVALE, N.J., Oct. 27 Memory,Pharmaceuticals Corp. (Nasdaq: ... U.S.,Patent No. 7,429,664, which provides composition of matter ... agonists. These,include R3487/MEM 3454 and R4996/MEM 63908, which ... the treatment of cognitive disorders such as,Alzheimer,s disease ...
... worship felines,like pharos; dog people talk to hounds like ... are different -- in marital status, economic,standing and education ... there are some interesting differences,between cat owners and dog ... Veterinary Medical Association (AVMA). "Our surveys show,that single people ...
Cached Medicine News:Health News: HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth 2Health News: HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth 3Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 2Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 3Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 4Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 5Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 6Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 7Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 8Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 9Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 10Health News:Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis 11Health News:Study Reveals Factors of Exceptional Health in Old Age 2Health News:Study Reveals Factors of Exceptional Health in Old Age 3Health News:Study Reveals Factors of Exceptional Health in Old Age 4Health News:Adaptis Names New Sales Executive 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Cat People vs. Dog People ... They Really are Different 2
(Date:7/28/2015)...  Insulet Corporation (NASDAQ: PODD ), the leader ... Insulin Management System, today announced that Dr. ... of Directors. Dr. Hopfield brings more than ... Board. She currently serves as the Vice Chair of ... largest diabetes research center, diabetes clinic, and provider of ...
(Date:7/28/2015)... 2015   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... quarter ended June 30, 2015 on Tuesday, August 4, ... Regulus will host a conference call and webcast ... Daylight Time to discuss its second quarter 2015 financial ...
(Date:7/28/2015)... Mass., July 28, 2015  Psychemedics Corporation (NASDAQ: ... the period ended June 30, 2015.  The Company also ... to shareholders of record as of August 7, 2015 ... be the Company,s 76 th consecutive quarterly dividend. ... June 30, 2015 was $7.0 million versus $7.7 million ...
Breaking Medicine Technology:Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Psychemedics Corporation Announces Second Quarter Earnings 2Psychemedics Corporation Announces Second Quarter Earnings 3Psychemedics Corporation Announces Second Quarter Earnings 4Psychemedics Corporation Announces Second Quarter Earnings 5Psychemedics Corporation Announces Second Quarter Earnings 6Psychemedics Corporation Announces Second Quarter Earnings 7Psychemedics Corporation Announces Second Quarter Earnings 8
... Genmab Initiates a Phase I/II Study of Zalutumumab in ... Advanced Head and Neck Cancer., COPENHAGEN, June 24 ... a Phase I/II study of zalutumumab,(HuMax-EGFr(TM)) in combination with ... The study will include a maximum of 36,patients who ...
... Biopharmaceuticals Plc, a,biopharmaceutical company focused on the development ... initiated a Phase II,equivalent study of MRX-4, in ... allergic rhinitis (AR). The two-arm, randomized, multi-dose,double-blind, placebo-controlled ... study is expected to be completed by the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis 2
... lead family features St. Jude ... The lead is available in ... and silicone (IsoFlex S lead) ... models, and multiple lead lengths, ...
... Veriteq's Refrigerator and Freezer Monitoring ... monitoring system for refrigerators and ... install. Using a building's existing ... Freezer monitoring solution automates the ...
Antiseptic - Antibacterial Sudsing Cleanser...
HIBICLENS' non-drying, low skin irritation potential promotes compliance with the frequent hand washing associated with today's clinical protocols....
Medicine Products: